Tofacitinib: a new oral Janus kinase inhibitor for psoriasis

被引：1
|
作者：
Gimenez-Arnau, A. M. [1 ]
机构：
[1] Univ Autonoma Barcelona, Hosp del Mar, Dept Dermatol, IMIM, Barcelona, Spain
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2019年 / 180卷 / 01期
关键词：
HERPES-ZOSTER; EFFICACY; MODERATE; VACCINE;
D O I：
10.1111/bjd.17323
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：13 / 14
页数：2
相关论文
共 50 条
  • [41] Tofacitinib: The First Janus Kinase (JAK) Inhibitor for the Treatment of Rheumatoid Arthritis
    Vyas, Deepti
    O'Dell, Kate M.
    Bandy, Jason L.
    Boyce, Eric G.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (11) : 1524 - 1531
  • [42] Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats
    Gwak, Eun Hye
    Yoo, Hee Young
    Kim, So Hee
    BIOMOLECULES & THERAPEUTICS, 2020, 28 (04) : 361 - 369
  • [43] Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis
    Dowty, Martin E.
    Jesson, Michael I.
    Ghosh, Sarbani
    Lee, Jamie
    Meyer, Debra M.
    Krishnaswami, Sriram
    Kishore, Nandini
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2014, 348 (01): : 165 - 173
  • [44] Glucocorticoid sparing in sarcoidosis using the Janus kinase (JAK) inhibitor tofacitinib
    Belliere, Julie
    Laurent, Camille
    Noel-Savina, Elise
    Pugnet, Gregory
    Faguer, Stanislas
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2022, 98 : 119 - 121
  • [45] Treatment of halo naevus with the topical Janus kinase inhibitor tofacitinib 1.5%
    Hu, W. T.
    Lin, F. Q.
    Xu, A. E.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2018, 43 (08) : 935 - 937
  • [46] Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions
    Fukuyama, Tomoki
    Tschernig, Thomas
    Qi, Yulin
    Volmer, Dietrich A.
    Baeumer, Wolfgang
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2015, 764 : 278 - 282
  • [47] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF MALIGNANCIES IN JAPANESE PATIENTS ACROSS THE RHEUMATOID ARTHRITIS CLINICAL PROGRAMME
    Tanaka, Y.
    Takeuchi, T.
    Yamanaka, H.
    Hirose, T.
    Toyoizumi, S.
    Zwillich, S.
    Geier, J.
    Riese, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 230 - 231
  • [48] ESTIMATED MEDICAL EXPENDITURES AMONG PATIENTS WITH RHEUMATOID ARTHRITIS UNDERGOING TREATMENT WITH TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR
    Rendas-Baum, R.
    Kosinski, M.
    Singh, A.
    Mebus, C.
    Wilkinson, B.
    Riese, R.
    Wallenstein, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 446 - 446
  • [49] Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis Pooled efficacy and safety analyses
    Lomonte, Andrea B. V.
    Radominski, Sebastiao C.
    Marcolino, Flora M. D.
    Brenol, Claiton V.
    Zerbini, Cristiano A. F.
    Garcia, Erika G.
    Akylbekova, Ermeg L.
    Rojo, Ricardo
    Ponce de Leon, Dario
    MEDICINE, 2018, 97 (31)
  • [50] Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Gastrointestinal Adverse Events Across The Rheumatoid Arthritis Clinical Program
    Lee, E. B.
    Curtis, J. R.
    Riese, R.
    Connell, C. A.
    Chew, R.
    Boy, M. G.
    Maller, E.
    Su, C.
    Wang, L.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S191 - S191
12345